Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination supplement containing curcumin (the primary polyphenolic compound from turmeric) and huperzine A (an alkaloid extracted from Huperzia serrata). This combination has been studied in patients with dementia, including Alzheimer’s disease, dementia with Lewy bodies, and mild cognitive impairment. The supplement is thought to improve cognitive function through multiple mechanisms. Curcumin exhibits anti-inflammatory, antioxidant, and chemoprotective properties[3]. Huperzine A acts as a potent cholinesterase inhibitor and glutamic acid receptor antagonist[1][2][4]. Clinical studies have shown significant improvements in cognitive function scores at 6–12 weeks and 22–28 weeks compared to baseline in open-label trials[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin + huperzine A.